WO1998011827A1 - Modulation of wound healing by photodynamic therapy - Google Patents
Modulation of wound healing by photodynamic therapy Download PDFInfo
- Publication number
- WO1998011827A1 WO1998011827A1 PCT/US1997/016188 US9716188W WO9811827A1 WO 1998011827 A1 WO1998011827 A1 WO 1998011827A1 US 9716188 W US9716188 W US 9716188W WO 9811827 A1 WO9811827 A1 WO 9811827A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- photosensitizer
- administration
- wound
- light
- photodynamic therapy
- Prior art date
Links
- 238000002428 photodynamic therapy Methods 0.000 title claims abstract description 41
- 230000029663 wound healing Effects 0.000 title abstract description 15
- 239000003504 photosensitizing agent Substances 0.000 claims abstract description 77
- 238000000034 method Methods 0.000 claims abstract description 39
- 210000002540 macrophage Anatomy 0.000 claims abstract description 38
- 206010016654 Fibrosis Diseases 0.000 claims abstract description 19
- 230000004761 fibrosis Effects 0.000 claims abstract description 19
- 230000008685 targeting Effects 0.000 claims abstract description 15
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 14
- 230000035876 healing Effects 0.000 claims abstract description 13
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 13
- 210000000651 myofibroblast Anatomy 0.000 claims abstract description 9
- 241000124008 Mammalia Species 0.000 claims abstract description 7
- 239000011859 microparticle Substances 0.000 claims abstract description 6
- 230000021615 conjugation Effects 0.000 claims abstract description 5
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 3
- 150000004032 porphyrins Chemical class 0.000 claims description 8
- 230000009885 systemic effect Effects 0.000 claims description 8
- 239000013307 optical fiber Substances 0.000 claims description 7
- 238000001356 surgical procedure Methods 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 6
- 150000004036 bacteriochlorins Chemical class 0.000 claims description 5
- 150000004035 chlorins Chemical class 0.000 claims description 5
- 208000031737 Tissue Adhesions Diseases 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 abstract description 38
- 206010052428 Wound Diseases 0.000 abstract description 34
- 210000004027 cell Anatomy 0.000 description 57
- 229920001223 polyethylene glycol Polymers 0.000 description 31
- 230000002186 photoactivation Effects 0.000 description 18
- 239000002202 Polyethylene glycol Substances 0.000 description 17
- 206010034972 Photosensitivity reaction Diseases 0.000 description 16
- 208000007578 phototoxic dermatitis Diseases 0.000 description 16
- 231100000018 phototoxicity Toxicity 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 210000002950 fibroblast Anatomy 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 239000003102 growth factor Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical class N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- 210000002919 epithelial cell Anatomy 0.000 description 7
- 230000037390 scarring Effects 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- 208000002847 Surgical Wound Diseases 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 5
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
- 125000002091 cationic group Chemical group 0.000 description 5
- -1 chlorin e6 Chemical class 0.000 description 5
- 231100000433 cytotoxic Toxicity 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 210000002510 keratinocyte Anatomy 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- KFKRXESVMDBTNQ-UHFFFAOYSA-N 3-[18-(2-carboxylatoethyl)-8,13-bis(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-21,24-diium-2-yl]propanoate Chemical compound N1C2=C(C)C(C(C)O)=C1C=C(N1)C(C)=C(C(O)C)C1=CC(C(C)=C1CCC(O)=O)=NC1=CC(C(CCC(O)=O)=C1C)=NC1=C2 KFKRXESVMDBTNQ-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 102000009618 Transforming Growth Factors Human genes 0.000 description 4
- 108010009583 Transforming Growth Factors Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- ISVXIZFUEUVXPG-UHFFFAOYSA-N etiopurpurin Chemical compound CC1C2(CC)C(C(=O)OCC)=CC(C3=NC(C(=C3C)CC)=C3)=C2N=C1C=C(N1)C(CC)=C(C)C1=CC1=C(CC)C(C)=C3N1 ISVXIZFUEUVXPG-UHFFFAOYSA-N 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000002435 tendon Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- OYINILBBZAQBEV-UWJYYQICSA-N (17s,18s)-18-(2-carboxyethyl)-20-(carboxymethyl)-12-ethenyl-7-ethyl-3,8,13,17-tetramethyl-17,18,22,23-tetrahydroporphyrin-2-carboxylic acid Chemical compound N1C2=C(C)C(C=C)=C1C=C(N1)C(C)=C(CC)C1=CC(C(C)=C1C(O)=O)=NC1=C(CC(O)=O)C([C@@H](CCC(O)=O)[C@@H]1C)=NC1=C2 OYINILBBZAQBEV-UWJYYQICSA-N 0.000 description 3
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 206010058029 Arthrofibrosis Diseases 0.000 description 3
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical class CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 3
- LBGCRGLFTKVXDZ-UHFFFAOYSA-M ac1mc2aw Chemical class [Al+3].[Cl-].C12=CC=CC=C2C(N=C2[N-]C(C3=CC=CC=C32)=N2)=NC1=NC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2[N-]1 LBGCRGLFTKVXDZ-UHFFFAOYSA-M 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- 210000001188 articular cartilage Anatomy 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 229960000907 methylthioninium chloride Drugs 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229940109328 photofrin Drugs 0.000 description 3
- 231100000760 phototoxic Toxicity 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 206010063560 Excessive granulation tissue Diseases 0.000 description 2
- 108010007979 Glycocholic Acid Proteins 0.000 description 2
- 101000859758 Homo sapiens Cartilage-associated protein Proteins 0.000 description 2
- 101000916686 Homo sapiens Cytohesin-interacting protein Proteins 0.000 description 2
- 101000726740 Homo sapiens Homeobox protein cut-like 1 Proteins 0.000 description 2
- 101000761460 Homo sapiens Protein CASP Proteins 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- 102000000853 LDL receptors Human genes 0.000 description 2
- 108010001831 LDL receptors Proteins 0.000 description 2
- 101000761459 Mesocricetus auratus Calcium-dependent serine proteinase Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 102100024933 Protein CASP Human genes 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- HUVXQFBFIFIDDU-UHFFFAOYSA-N aluminum phthalocyanine Chemical class [Al+3].C12=CC=CC=C2C(N=C2[N-]C(C3=CC=CC=C32)=N2)=NC1=NC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2[N-]1 HUVXQFBFIFIDDU-UHFFFAOYSA-N 0.000 description 2
- 229960002749 aminolevulinic acid Drugs 0.000 description 2
- 238000001949 anaesthesia Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000004700 cellular uptake Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 2
- 210000001126 granulation tissue Anatomy 0.000 description 2
- 230000002962 histologic effect Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229950003776 protoporphyrin Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- RLLPVAHGXHCWKJ-IEBWSBKVSA-N (3-phenoxyphenyl)methyl (1s,3s)-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate Chemical compound CC1(C)[C@H](C=C(Cl)Cl)[C@@H]1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-IEBWSBKVSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- KHUFHLFHOQVFGB-UHFFFAOYSA-N 1-aminoanthracene-9,10-dione Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2N KHUFHLFHOQVFGB-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- RHBJMYOTXIENOZ-UHFFFAOYSA-N 2-[10,15,20-tris(2-hydroxyphenyl)-21,23-dihydroporphyrin-5-yl]phenol Chemical class Oc1ccccc1-c1c2ccc(n2)c(-c2ccccc2O)c2ccc([nH]2)c(-c2ccccc2O)c2ccc(n2)c(-c2ccccc2O)c2ccc1[nH]2 RHBJMYOTXIENOZ-UHFFFAOYSA-N 0.000 description 1
- CIHKVMHPDDJIIP-UHFFFAOYSA-N 2-methylperoxybenzoic acid Chemical compound COOC1=CC=CC=C1C(O)=O CIHKVMHPDDJIIP-UHFFFAOYSA-N 0.000 description 1
- BTQAFTBKHVLPEV-UHFFFAOYSA-N 3h-naphtho[2,3-e]indazole Chemical class C1=CC=CC2=CC3=C4C=NNC4=CC=C3C=C21 BTQAFTBKHVLPEV-UHFFFAOYSA-N 0.000 description 1
- 206010000050 Abdominal adhesions Diseases 0.000 description 1
- 241001263178 Auriparus Species 0.000 description 1
- 108010003118 Bacteriochlorophylls Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010023201 Joint contracture Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- HAQIAMKYUYMCQU-UHFFFAOYSA-N N-[2-[10,15,20-tris[2-(propanoylamino)phenyl]-21,23-dihydroporphyrin-5-yl]phenyl]propanamide Chemical compound C(CC)(=O)NC1=C(C=CC=C1)C1=C2C=CC(C(=C3C=CC(=C(C=4C=CC(=C(C5=CC=C1N5)C5=C(C=CC=C5)NC(CC)=O)N4)C4=C(C=CC=C4)NC(CC)=O)N3)C3=C(C=CC=C3)NC(CC)=O)=N2 HAQIAMKYUYMCQU-UHFFFAOYSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000999 acridine dye Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 210000001264 anterior cruciate ligament Anatomy 0.000 description 1
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical class C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- XZSVAMUZTKNGDN-JBRJOJLESA-L bacteriochlorophylls Chemical compound [Mg+2].[N-]1C2=C(C=3C(C(C)C(=CC=4C(=C(C(C)=O)C(=C5)N=4)C)N=3)CCC(=O)OC\C=C(/C)CCCC(C)CCCC(C)CCCC(C)C)C(C(=O)OC)C([O-])=C2C(C)=C1C=C1C(CC)C(C)C5=N1 XZSVAMUZTKNGDN-JBRJOJLESA-L 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000002442 collagenase inhibitor Substances 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- VHILMKFSCRWWIJ-UHFFFAOYSA-N dimethyl acetylenedicarboxylate Chemical class COC(=O)C#CC(=O)OC VHILMKFSCRWWIJ-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000002683 hand surgery Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229960003569 hematoporphyrin Drugs 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940028435 intralipid Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012829 orthopaedic surgery Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002399 phagocytotic effect Effects 0.000 description 1
- 230000002165 photosensitisation Effects 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 230000025902 positive regulation of locomotion Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009430 psychological distress Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000008215 regulation of wound healing Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 108010078070 scavenger receptors Proteins 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940066767 systemic antihistamines phenothiazine derivative Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- NLDYACGHTUPAQU-UHFFFAOYSA-N tetracyanoethylene Chemical group N#CC(C#N)=C(C#N)C#N NLDYACGHTUPAQU-UHFFFAOYSA-N 0.000 description 1
- YNHJECZULSZAQK-UHFFFAOYSA-N tetraphenylporphyrin Chemical class C1=CC(C(=C2C=CC(N2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3N2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 YNHJECZULSZAQK-UHFFFAOYSA-N 0.000 description 1
- 238000011541 total hip replacement Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/932—Specified use of nanostructure for electronic or optoelectronic application
Abstract
Disclosed is a method for modulating wound healing in a mammal. The method includes the steps of: (a) administering a photosensitizer to a mammal that has an unhealed or partially-healed wound; (b) waiting for the photosensitizer to reach an effective tissue concentration at the wound site; (c) photoactivating the photosensitizer by delivering specifically to the wound site light of an effective wavelength and intensity, for an effective length of time. The modulation of wound healing can include hastening healing by administering a low dose of photodynamic therapy. Alternatively, the modulation can include inhibiting fibrosis by administering a high dose of photodynamic therapy. The photosensitizer can be targeted, for example, to macrophages or myofibroblasts. Targeting can be by conjugation to a targeting moiety such as a protein, peptide or microparticle.
Description
MODULATION OF WOUND HEALING BY PHOTODYNAMIC THERAPY CROSS-REFERENCE TO RELATED APPLICATION This application claims benefit from United States provisional application Serial No. 60/026,315, filed September 19, 1996.
Field of the Invention This invention relates to wound healing and photodynamic therapy. Background of the Invention
Dysfunctional healing can involve a slowing of the process, which can lead to indolent and chronic wounds. Such slowing can be due to factors such as hemorrhagic shock, infection, immune suppression, or prolonged psychological distress. Alternatively, dysfunctional healing can involve a hyperproliferative response, which can lead to, e.g., post-surgical adhesions.
Macrophages are central to the complex process of wound healing, which involves removal of dead tissue, formulation of granulation tissue, neovascularization, stimulation of locomotion and proliferation of fibroblasts and keratinocytes, and production of collagen types I and III. Photodynamic therapy can destroy large amounts of tissue with a good healing response and good cosmetic result (Koren et al, Int . J. Radiat . Oncol . Biol . Phys . 28:463-466 (1994)). Photodynamic therapy can be used either to stimulate or suppress cellular responses such as cytokine release and immune function. Whether the photodynamic therapy causes stimulation or suppresion depends on the dosage. Low dose photodynamic therapy stimulates cytokine release and immune function, while high dose photodynamic therapy suppresses those processes (Obochi et al., SPIE Proc . 2675:122-131 (1996); Ya amoto et al., Photoche . Photobiol . 60:160-164 (1994)) .
Photodynamic therapy has major effects on macrophages. Low dose photodynamic therapy activates macrophages. This enhances their cytotoxicity against tumor cells (Yamamoto et al., Photobiol . B 13:295-306 (1992)). High dose photodynamic therapy leads to production of TNF alpha, and eventually, macrophage death (Evans et al., J . Natl . Cancer Inst . 82:34-39 (1990)).
Fibrosis is a response to injury in which new extracellular matrix is rapidly laid down producing dense bands of collagen that are the microscopic hallmark of scarring. The extent and duration of fibrosis often far exceeds the apparent need for wound healing, causing hypertrophic scars and contractures that limit function or distort anatomy. In the peritoneum, joints, tendon sheaths, or essentially any body space with an epithelial lining, injury and fibrosis can lead to adhesions which bind tissues together. Scars remain metabolically hyperactive long after injury, both producing and degrading extracellular matrix at a rate many times that of uninjured tissue.
The initiation and control of many concerted processes responsible for wound healing are governed by molecules which direct cell activity such as cytokines, growth factors, and adhesion molecules. In particular, the extracellular matrix growth factors TGF-/3, platelet derived growth factor (PDGF) , and basic fibroblast growth factor (bFGF) appear to initiate and/or sustain fibrosis. Specifically TGF-9 appears to be the dominant cytokine governing the aggressiveness of the scarring response. TGF-7 has been implicated in hepatic fibrosis, pulmonary fibrosis, scleroderma, and keloids. It stimulates collagen and fibronectin formation, suppresses collagenase and induces production of collagenase inhibitors. Increased TGF-? levels, increasing scarring, and more rapid healing responses are associated with
disorientation and thinning of type I collagen fibers with abnormal production of proteoglycans and glycosaminoglycans in wound extracellular matrix.
Photodynamic therapy has been used to treat cancer. See, e.g., Dougherty et al.. In Photodynamic Therapy of Neoplastic Disease , (Kessel, ed.), CRC Press, Boca Raton, FL (1989) . Photodynamic therapy has also been used for destruction of the synovium in the treatment of rheumatoid arthritis (U.S. Patent No. 5,368,841).
Summary of the Invention The invention features a method for modulating the healing of a wound in a mammal. The method includes the steps of: (a) administering an effective amount of a photosensitizer to a mammal that has an unhealed or partially-healed wound; (b) waiting for a time period wherein the photosensitizer reaches an effective tissue concentration at the wound site; (c) photoactivating the photosensitizer at the wound site by delivering specifically to the wound site light of a effective wavelength and intensity, for an effective length of time. The modulation of wound healing can include hastening healing by administering a low dose of photodynamic therapy. Alternatively, the modulation can include inhibiting fibrosis by administering a high dose of photodynamic therapy.
Photosensitizers include members of the following classes of compounds: porphyrins, chlorins, bacteriochlorins, purpurins, phthalocyanines, naphthalocyanines, texaphyrins, and non-tetrapyrrole photosensitizers. Specific examples include Photofrin, benzoporphyrin derivative, tin etiopurpurin, sulfonated chloroaluminum phthalocyanine and methylene blue. The photosensitizer can be targeted, for example, to macrophages or myofibroblasts, by conjugation to a
targeting moiety such as a protein, peptide, or microparticle. Administration of the photosensitizer can be local or systemic. For systemic administration, the preferred dosage is between about 0.1 g/kg and about 50 mg/kg. More preferably, it is at a dosage level between about 0.5 mg/kg and about 10 mg/kg. In other embodiments of the invention, the administration of the photosensitizer is local. Local administration can be perilesional or topical. Light for photoactivation of the photosensitizer can be delivered to the wound site using various light sources and various means of delivery. For superficial wounds or open surgical wounds, suitable light sources include broadband conventional light sources, broad arrays of LEDs, and defocussed laser beams. For deeper wound sites, including those in intracavitary settings, useful means of light delivery include optical fiber devices and transillumination. The invention can be used prophylactically, i.e., before surgery, to modulate the healing of surgical wounds. Such modulation can be used to reduce surgical adhesions, e.g., intrapleural adhesions, intraperitoneal adhesions, tendon sheath adhesions, and intraarticular adhesions. As used herein, "low dose" photodynamic therapy means a dose sufficient to kill from 0% to about 10% of all cells exposed to the photoactiviting light if the photosensitizer is untargeted, or from 0% to about 10% of the targeted cells exposed to the photoactiviting light, if the photosensitizer is targeted.
As used herein, "high dose" photodynamic therapy means a dose sufficient to kill from about 10% to about 90% of all cells exposed to the photoactivating light if the photosensitizer is untargeted, or from about 10% to about 90% of the targeted cells exposed to the
photoactivating light, if the photosensitizer is targeted. The dose of photodynamic therapy is calculated as the product of photosensitizer dose and photoactivating light dose. Thus, photodynamic therapy dose can be adjusted by adjusting the photosensitizer dose, photoactivating light dose, or both.
As used herein, "photoactivation" means a light-induced chemical reaction of a photosensitizer which produces a biological effect. As used herein, "photosensitizer" means a chemical compound that produces a biological effect upon photoactivation, or a biological precursor of a compound that produces a biological effect upon photoactivation. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present document, including definitions, will control. Unless otherwise indicated, materials, methods, and examples described herein are illustrative only and not intended to be limiting.
Various features and advantages of the invention will be apparent from the following detailed description and from the claims.
Brief Description of the Drawings Fig. 1 is a graph of haematoporphyrin uptake per g of cell protein, as a function of the concentration of haematoporphyrin equivalents. This graph summarizes the results of experiments performed to
demonstrate selective targeting of low density lipoprotein-haematoporphyrin conjugates (LDL-HP) to macrophages. Solid line, LDL-HP taken up by fibroblasts; broken line with open circles, LDL-HP taken up by macrophages; broken line with open squares, unconjugated haematoporphyrin taken up by macrophages.
Fig. 2 is a bar graph summarizing the results of experiments on uptake of various ce6 conjugates by two types of cultured cells (J774, dark bars; OV-5, light bars) .
Fig. 3A is a graph showing the results of experiments on phototoxicity of pl-ce6 (closed squares) and pl-ce6-PEG (open circles) on OVCAR-5 cells.
Fig. 3B is a graph showing the results of experiments on phototoxicity of pl-ce6-ac (closed squares) and pl-ce6-ac-PEG (open circles) on OVC.AR-5 cells.
Fig. 3C is a graph showing the results of experiments on phototoxicity of pl-ce6-succ (closed squares) and pl-ce6-succ-PEG (open circles) on OVCAR-5 cells.
Fig. 3D is a graph showing the results of experiments on phototoxicity of pl-ce6 (closed squares) and pl-ce6-PEG (open circles) on J774 cells. Fig. 3E is a graph showing the results of experiments on phototoxicity of pl-ce6-ac (closed squares) and pl-ce6-ac-PEG (open circles) on J774 cells.
Fig. 3F is a graph showing the results of experiments on phototoxicity of pl-ce6-succ (closed squares) and pl-ce6-succ-PEG (open circles) on J774 cells.
Fig. 4 is a graph showing relative phototoxicity (reciprocal of survival at each light dose divided by uptake in nmol ce6/mg cell protein) . OV5 cells and pl-ce6, open triangles; OV5 cells and pl-ce6-
PEG, open circles; J774 cells and pl-ce6, open squares; J774 cells and pl-ce6-PEG, closed circles.
Fig. 5 is a graph showing relative phototoxicity (reciprocal of survival at each light dose divided by uptake in nmol ce6/mg cell protein) . 0V5 cells and pl-ce6-ac, open triangles; 0V5 cells and pl- ce6-ac-PEG, open circles; J774 cells and pl-ce6-ac, open squares; J774 cells and pl-ce6-ac-PEG, closed circles. Fig. 6 is a graph showing relative phototoxicity (reciprocal of survival at each light dose divided by uptake in nmol ce6/mg cell protein) . OV5 cells and pl-ce6-succ, open triangles; 0V5 cells and pl- ce6-succ-PEG, open circles; J774 cells and pl-ce6-succ, open squares; J774 cells and pl-ce6-succ-PEG, closed circles.
Detailed Description The present invention involves applying photodynamic therapy ("PDT") to an unhealed or partially healed wound. In general, photodynamic therapy involves administration of a photosensitizer to a patient, followed by photoactivation of the photosensitizer, to produce a cytotoxic effect. In the present invention, photoactivating light is delivered specifically to an unhealed or partially-healed wound, where the biological effect modulates wound healing.
The modulation of wound healing can be achieved according to this invention by modulating macrophage function, yofibroblast function, endothelial cell function, or any combination thereof, through photodynamic therapy at a wound site. Preferaby, the photodynamic therapy includes targeting a photosensitizer to macrophages and myofibroblasts. Targeting can be accomplished, for example, by conjugating the photosensitizer to a targeting moiety that binds to a receptor on the macrophage or myofibroblast surface,
e.g., an LDL receptor or a "scavenger" receptor. Alternatively, macrophage targeting can be accomplished by exploiting the phagocytosis that characterizes macrophages and myofibroblasts. The photosensitizer can be conjugated to a microparticle, e.g., a 1 μm polystyrene microsphere (Polysciences, Inc.). such photosensitizer-microparticle conjugates are taken up selectively by macrophages and myofibroblasts, due to phagocytotic activity of those cell types. A photosensitizer-microparticle conjugate can be produced by known methods, e.g., those described in Bachor et al., Proc . Natl . Acad . Sci . USA 88:1580-1584 (1991).
Fibrosis is a complex process involving different cell types such as fibroblasts, myofibroblasts, and macrophages. Fibrosis also involves interactions between cells by means of biologically active molecules such as growth factors, cytokines, and cell adhesion molecules. Therefore, fibrosis can be advantageously inhibited according to the present invention in various ways. For example, in one embodiment of the invention inhibition of fibrosis results from localized killing of cells involved in fibrosis, e.g., macrophages. Such localized killing can be rendered selective for a particular cell type through the use of a targeted photosensitizer. Preferably, the inhibition of fibrosis results from localized inactivation of extracellular growth factors or cytokines. More preferably, it results from inactivation of TGF-3 or bFGF. Inhibition of fibrosis according to this invention can involve one or more of the following: decreased collagen production, modified collagen cross-linking, changes in remodeling of the extracellular matrix, and breakdown of collagen.
Inhibiting fibrosis according to the present invention is a useful adjunct to surgical practice in general. Post operative scarring and fibrosis in the
healing of surgical incisions is a common complication from surgery. In hand surgery, excessive scarring of skin can cause joint contracture. Any joint subjected to surgery or injury is at risk of arthrofibrosis. Tendon repair surgery can result in adhesions surrounding the tendon repair. In reconstructive orthopaedic surgery, stiffness and decreased range of motion often follow surgery and compromise clinical outcome. Arthrofibrosis is a frequent complication of procedures such as anterior cruciate ligament reconstruction and total hip replacement. Intraabdominal adhesions are a frequent complication following abdominal surgery. This invention is useful in all such surgical situations. The present invention can also be used to inhibit fibrosis and excessive scarring in the healing of wounds other than surgical incisions. Photosensitizer
The photosensitizer is a chemical compound that produces a biological effect upon photoactivation, or a biological precursor of a compound that produces a biological effect upon photoactivation. The photosensitizer must have a sufficiently low toxicity to permit administration to the patient with a medically acceptable level of safety. Preferably, the photosensitizer is essentially nontoxic, except for the desired cytotoxic effect produced locally, upon photoactivation.
Various photosensitizers are known and can be used in the practice of this invention. Photosensitizers typically have chemical structures that include mutiple conjugated rings that allow for light absorption and photoactivation. They differ in the properties of light absorption and fluorescence, biodistribution, temporal uptake, clearance, and mechanisms of photoactivatable cytotoxicity. Classes of photosensitizers include
hematoporphyrins (Batlle, J . Photochem . Photobiol . B -
Biol . 20:5-22 (1993); Kessel, Cancer Let . 39:193-198
(1988)), uroporphyrins, phthalocyanines (Kreimer-
Birnbaum, Seminars in Hematology 26:157-173 (1989)), purpurins (Morgan et al., Photochem . Photobiol . 51:589-
592 (1990); Kessel, Photochem . Photobiol . 50:169-174
(1989)), acridine dyes, bacteriochlorophylls (Beems et al., Photochem . Photobiol . 46:639-643 (1987); Kessel et al., Photochem . Photobiol . 49:157-160 (1989)), and bacteriochlorins (Gurinovich et al., J . Photochem .
Photobiol . B - Biol . 13:51-57 (1992)). Specific examples of suitable photosensitizers are listed in Table 1.
TJVBLE 1
Photosensitizers 1. Photofrin®
2. Synthetic diporphyrins and dichlorins
3. Hydroporphyrins, e.g., chlorins and bacteriochlorins of the tetra(hydroxyphenyl) porphyrin series 4. phthalocyanines
5. O-substituted tetraphenyl porphyrins (picket fence porphyrins)
6. 3,1-meso tetrakis (o-propionamido phenyl) porphyrin 7. Verdins
8. Purpurins, e.g., tin and zinc derivatives of octaethylpurpurin (NT2) , and etiopurpurin (ET2) 9. Chlorins, e.g., chlorin e6, and mono-1-aspartyl derivative of chlorin e6 10. Benzoporphyrin derivatives (BPD) , e.g., benzoporphyrin monoacid derivatives, tetracyanoethylene adducts of benzoporphyrin, dimethyl acetylenedicarboxylate adducts of benzoporphyrin, Diels-Adler adducts, and monoacid ring "a" derivative of benzoporphyrin 11. Low density lipoprotein mediated localization parameters similar to those observed with hematoporphyrin derivative (HPD) 12. sulfonated aluminum phthalocyanine (Pc) sulfonated AlPc disulfonated (AlPcS2)
tetrasulfonated derivative sulfonated aluminum naphthalocyanines chloroaluminum sulfonated phthalocyanine (CASP)
13. zinc naphthalocyanines
14. anthracenediones
15. anthrapyrazoles
16. aminoanthraquinone 17. phenoxazine dyes
18. phenothiazine derivatives
19. chalcogenapyrylium dyes cationic selena and tellurapyrylium derivatives 20. ring-substituted cationic PC
21. pheophorbide
22. hematoporphyrin (HP)
23. protoporphyrin
24. 5-amino levulinic acid Photosensitizers include members of the following classes of compounds: porphyrins, chlorins, bacteriochlorins, purpurins, phthalocyanines, naphthalocyanines, texaphyrines, and non-tetrapyrrole photosensitizers. Specific examples are Photofrin, benzoporphyrin derivative, tin etiopurpurin, sulfonated chloroaluminum phthalocyanine and methylene blue. BPD is a second generation porphyrin photosensitizer that diffuses rapidly from microvasculature and disseminates throughout a joint. In addition, BPD has a low affinity for chondrocytes and articular cartilage following systemic or intra-articular injection. CASPc, a phthalocyanine inactivates growth factors TGF-jS and bFGF.
A single photosensitizer compound can be used alone in the practice of this invention. Alternatively, two or more photosensitizers can be used in combination, provided that light of a effective wavelength for each photosensitizer in the combination is used in the photoactivation step.
An alternative to administration of the photosensitizer compound itself, is administration of a photosensitizer precursor molecule. This approach is
illustrated by the use of 5-aminolevulinic acid, which causes endogenous production of the photosensitizer protoporphyrin IX (Morgan et al., J. Med . Chem . 32:904- 908 (1989). The mechanism of the biological effect produced upon photoactivation need not be of a particular type, as long as the desired inhibition of fibrosis is achieved. The mechanism of the cytotoxic effect will depend upon the particular photosensitizer used. Typically, the cytotoxic effect results from the generation of a shortlived, highly reactive, diffusible species such as singlet oxygen or free radicals. Singlet oxygen or free radicals can then react with double bonds and initiate free radical chain reactions which can inactivate biologically active molecules such as growth factors or cytokines. Such a reaction process can also degrade or disorganize biological membranes of cells that participate directly or indirectly in fibrosis. The photosensitizer can be chosen, or chemically modified, to optimize its usefulness in specific treatment situations. For example, the photosensitizer can be chemically modified to reduce its interaction with articular cartilage, when used to inhibit arthrofibrosis. This could be done by eliminating a positive charge to reduce association with negatively charged proteoglycans of articular cartilage. For targeting to a particular organ or tissue, the photosensitizer can be chemically conjugated to a targeting moiety such as a monoclonal antibody. The photosensitizer can be formulated to optimize its usefulness for particular applications. For example, it can be formulated in a salve or gel for topical application. It can be formulated for parenteral administration or oral administration. Appropriate
formulation can be carried out by one of ordinary skill in the art, without undue experimentation.
Administration of the photosensitizer can be local or systemic. The administration can be by any suitable route, including topical, intravenous, intraarticular, subcutaneous, intramuscular, intraventricular, intracapsular, intraspinal, intraperitoneal, topical, intranasal, oral, buccal, rectal or vaginal. The preferred route of administration will depend on the size and nature of the wound, and on the location of the wound.
Parenteral formulations may be in the form of liquid solutions or suspensions; for oral administration, formulations may be in the form of tablets or capsules; and for intranasal formulations, in the form of powders, nasal drops, or aerosols.
Methods well known in the art for making formulations are to be found in, for example, "Remington's Pharmaceutical Sciences." Formulations for parenteral administration may, for example, contain as excipients sterile water or saline, Cremophor EL, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated naphthalenes, biocompatible, biodegradable lactide polymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the present factors. Other potentially useful parenteral delivery systems for the factors include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, liposomes, and antibody conjugates. Formulations for inhalation may contain as excipients, for example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or may be oily solutions for administration in the form of nasal drops, or as a gel to be applied
intranasally. Formulations for parenteral administration may also include glycocholate for buccal administration, methoxysalicylate for rectal administration, or citric acid for vaginal administration. Where the size, nature, and location of the wound being treated renders local administration of the photosensitizer feasible, local administration is preferred over systemic administration. Local adminstration generally reduces the likelihood of unwanted side effects. In addition, it typically permits greater control over photosensitizer concentration at the wound site. Photoactivation
In preferred embodiments of the invention, the method includes a waiting step between the step of administering the photosensitizer and the step of photoactivating the photosensitizer. The waiting step is designed to allow the photosensitizer to reach an optimal tissue concentration at the wound site, prior to photoactivation. The length of the waiting step will depend on factors such as the route by which the photosensitizer is administered, the location of the wound, and the speed with which the photosensitizer moves in the body. Typically, the waiting step will be longer when the photosensitizer is administered systemically. The wound site is exposed to light of an effective wavelength and intensity, for an effective length of time. What wavelength, or range of wavelengths, is effective will depend on the photosensitizer(s) used. Wavelength specificity for photoactivation depends on the molecular structure of the photosensitizer. Photoactivation occurs with sub- ablative light doses.
Preferably, delivery of the light used to photoactivate the photosensitizer is limited to the wound
site and the area immediately surrounding the wound site. This minimizes undesirable cytotoxic side effects.
The light for photoactivation can be produced and delivered to the wound site by any suitable means. For example, the light can be delivered via optical fibers threaded through small gauge hypodermic needles. Alternatively, the light can be provided extracorporeally by transillumination. Some photosensitizing compounds can be activated by near infrared and longer wavelength visible light. This allows deeper tissue penetration of the photoactivating light, thereby facilitating transillumination. Optical fibers can be passed via arthroscopes with direct visual targeting and activation of the compounds. Optical fibers can also be passed directly via small gauge hypodermic needles. Light can also be transmitted via percutaneous instrumentation using optical fibers or cannulated waveguides. Transillumination can be performed using a variety of devices. The devices can utilize laser or non-laser sources, i.e. lightboxes or convergent light beams.
Photoactivation can also be performed by open arthrotomy.
Targeting cells involved in the wound healing process may require conjugates that discriminate between different cell types. One example of this is the ability to discriminate between macrophages and epithelial cells. This may have significance in the wound healing situation, because it may be desirable to stimulate or to inhibit macrophage function, while leaving epithelial cell function relatively unaltered. Other disorders of wound healing may require the stimulation or inhibition of epithelial cell function while leaving macrophages unaltered. The attachment of PEG may be a way of "switching" the effect from one cell type to another.
The following experimental examples are intended to be illustrative and not limiting of the invention.
Experimental Information
Selective Uptake of LDL-HP bv Macrophages
Experiments have been carried out to demonstrate selective uptake of low density lipoprotein- haematoporphyrin conjugates (LDL-HP) by J774 macrophages, as compared to 3T3 fibroblasts. As a negative control, uptake of unconjugated HP by the macrophages was also measured. The macrophage uptake of LDL-HP was approximately 9-fold greater than macrophage uptake of unconjugated HP (Fig. 1) . Macrophage uptake of LDL-HP was approximately 13-fold greater than fibroblast uptake of LDL-HP (Fig. 1) .
In the LDL-HP uptake experiments, LDL-HP was prepared essentially as described in Hamblin et al, J. Photochem . Photobiol . B 26:45-56 (1994)). Heamatoporphyrin N-hydroxysuccinamide ester (HP-NHS) was prepared by mixing 20 umol HP with 40 um NHS and 40 umol DCC in 2 ml dry dimethyl sulfoxide, and leaving the mixture in the dark at room temperature overnight. Conjugation to low density lipoprotein was performed by dissolving 10 mg of protein in 2 ml of 0.1 M HP-NHS solution. The solution was mixed thoroughly and allowed to stand overnight at room temperature. All subsequent operations with conjugates were carried out in subdued light. The crude conjugation reaction product was applied to a column of Sephadex G50 and eluted with 5 mM NaHC03 (pH 8) . The brown band of protein conjugate rapidly separated from the red band of free porphyrin. The conjugates were stored at -20 C, in solutions containing 10-20% glycerol.
The cell lines were grown in 1:1 Dulbecco's modified Eagle medium (DMEM)-Hams F12 medium supplemented with glutamine, antibiotics, and 10% fetal calf serum. Experimental cultures were grown to semi-confluence in 24-well tissue culture plates containing 1 ml medium per well. The medium was replaced and conjugates were added in phosphate-buffered saline (PBS) . Free photosensitizer was added in a small volume (5 μl) of dimethyl sulfoxide. At the end of incubation, the medium was removed, the cells were washed with PBS (3 x 1 ml) and incubated with trypsin-EDTA for 10 minutes (3T3 fibroblasts) or one hour (J774 macrophages) . The cells were centrifuged, and the pellet (usually fluorescent under long-wave UV) was dissolved in 1 ml of a mixture of 1% sodium dodecylsulfate (SDS) and 0.1 M NaOH. The fluorescence of the cell extract was measured (emission, 632 nm; excitation 412 nm) and the protein content was determined by the Lowry method. Results were expressed as fluorescence units per mg of cell protein. One fluorescence unit per milligram of protein is approximately equal to 1.7 pmol porphyrin per milligram of cell protein, i.e., about 106 molecules porphyrin per cell.
Modulation of TGF βl Levels in Cultured Cells by Photodynamic Treatment
Balb/mk murine keratinocytes were grown to 60% confluency in P100 dishes in medium containing 10% FBS.
The cells were incubated with pl-ce6-succ (d.p. 100, substitution ratio <5%) at the indicated concentration of ce6 equivalent for 4 hours, followed by delivery of the indicated fluence of red light from a light emitting diode array centered on 670 nm. After 24 hours, the cells were lysed, and equal amounts of cell protein (25 μg per lane) were loaded onto a 15% SDS PAGE gel. After
electrophoresis, bands from the gel were electroblotted onto a nylon membrane, which was probed with anti-TGF^l antibody. The bound murine anti TGF71 was then detected by a secondary antibody conjugated to alkaline peroxidase.
At fluence of 5Jcm-2, there was an increase of TGF,βl after incubation with 0.5 μM ce6 equivalent. This increase was greater after incubation with 2 μM ce6 equivalent. Twenty J cm-2 after 2 μM incubation produced substantial phototoxicity to the cells, which accounted for the reduced TGF91.
These results indicated that the conjugate plus light increased cellular expression of the gene for TGF/91, or it caused TGF31 which would have been released to the medium to be retained in the cell. It is believed that this was the first time photodynamic treatment had been shown to affect levels of TGF/S1.
Modification of Cell Type Selectivity of Poly-L-Lysine e6 Conjugates by Attachment of Polyethylene Glvcol
Poly-1-lysine of d.p. 100 was conjugated to chlorin e6 to produce pl-ce6 with a substitution ratio of approx 4%. This pl-ce6 was divided into two aliquots.
One aliquot was covalently attached to polyethylene glycol (PEG) by reaction with carbonyl-imidazolyl-PEG to produce pl-ce6-PEG. Each of these two aliquots was divided into three subaliquots. One subaliquot from each was left unaltered. The second was exhaustively acetylated with acetic anhydride to produce pl-ce6-ac and pl-ce6-PEG-ac respectively. The third subaliquot was similarly exhaustively succinylated with succinic anhydride to produce pl-ce6-succ and pl-ce6-PEG-succ, respectively. After purification by exhaustive dialysis, these six preparations were tested for their uptake and
phototoxicity on J774 mouse macrophages and OVCAR-5 ovarian cancer epithelial cells.
Fig. 2 is a bar graph summarizing cellular uptake data from experiments involving the six conjugates and the two cell lines. In general, the macrophages took up more than the epithelial cells, and the PEG conjugates were taken up between one half and one quarter as much as their non-PEG counterparts.
Figs. 3A-3F show phototoxicity in terms of a dose response curve for the six conjugates and the two cell lines. For OVCAR-5 cells: cationic pl-ce6-PEG was the most phototoxic, pl-ce6 (non-PEG) was less phototoxic; for the neutral conjugates, pl-ce6-ac was more phototoxic than pl-ce6-ac; and for the anionic conjugates, there was little difference between PEG and non-PEG. For J774 cells: cationic PEG and non-PEG were similarly low in phototoxicity; for the neutral conjugates, the non-PEG pl-ce6-ac was more toxic than the PEG; for the anionic conjugates, the non-PEG was much more toxic than the PEG.
Figs. 4-6 show the relative phototoxicity of the six conjugates and the two cell lines. Here, the phototoxicity was corrected for differences in cellular uptake. Attachment of PEG increased the phototoxicity of the cationic conjugate and the acetylated conjugate towards epithelial cells, and slightly reduced it towards macrophages. For the anionic conjugates the effect on the epithelial cells was less marked, while that on the macrophages was more marked. The following experimental protocols provide additional guidance enabling one of ordinary skill in the art to practice the present invention.
Macrophage Targeted Photodynamic Regulation of Wound Healing
In this protocol, 64 hairless rats receive multiple surgical incisions to their backs. Incisions are applied at 2 time points prior to, and 1 time point after, application of photodynamic therapy. The photodynamic therapy entail systemic or local photosensitizer administration followed by regional light therapy. For each treatment, either for surgical incisions, PDT treatment, or biopsy, animals are sedated with general anesthesia. Anesthesia is induced using an intramuscular injection of either Ketamine (80 mg/kg) , or Xylazine (12 mg/kg) . Anaesthesia is determined approximately 15 minutes post-injection by the absence of spontaneous movement, with maintenance of spontaneous respiration. The assessment of deep anaesthesia is determined every 15 minutes by gentle touching of the edge of the sclera with a cotton swab to look for the blinking response. Reinjection of the anaesthetic is done only if necessary. During the experiment, care is taken to keeping the animals warm, such as by placing them on a warm table. Postoperatively, pain is monitored by observation of behavior. Pain control is provided with buprenorphine 0.03 mg/kg SQ, q 12 hrs.
At 3 days prior to, one hour prior to, and one hour after photodynamic treatment, a series of full thickness incisions are made with a # 10 scalpel blade on the back of each animal. Incisions are 25 mm in length, and spaced 1 inch apart. At time 0, rats 1-24 receive systemic injection of varying concentrations (0.5 mg/kg to 10 mg/kg) of CASP via a 30 gauge needle into the tail vein. Wounds are irradiated with 25, 50 or 100J laser energy at a wavelength of 675nm at 5, 180 minutes, and 24 hours post injection. Animals 25-48 are treated with topical application of methylene blue 5 minutes before,
and one hour before, photo activation. Using similar laser treatment parameters, 660 nm light is applied to the incision sites. Animals 49-56 are treated with systemic injections of BPD-MA (0.5 mg/kg to 10 mg/kg) and 692 nm light. Animals 57-64 are treated with systemic injections of SnEt2 (0.5 mg/kg to 5 mg/kg) and 700 nm light. Incisions sites not exposed with light serve as controls. Dark toxicity controls are performed for each photosensitizer. At 1 day, one week, 2, 4, 8 and 10 weeks post treatment, incisions are harvested as 5 mm X 25 mm specimens and serially sectioned into 1 mm thick specimens. Biopsy sites are closed with interrupted 3-0 nylon suture. Wounds at each time point prior to biopsy are photographed and degree of scarring evaluated by visual analogue and categorical scales. For each time point, specimens are fixed, sectioned and stained with H+E for histologic evaluation. Immunofluorescence staining of histologic sections are performed for growth factors and their receptors, to determine the depth of effect below the skin surface. Instron testing on three 1 mm thick strips are performed to characterize tensile strength of the wound repair. TGF-.β, bFGF, and PDGF tissue concentrations are quantified by RIA on specimens weighed immediately post harvest. mRNA levels, reflecting growth factor production, are assessed by Northern blot techniques or RNase protection assays, if greater sensitivity is required. Type I collagen content is measured by hydroxyproline assay. Collagen synthesis is assayed by measurement of tritiated hydroxyproline incorporation. GAG content is evaluated by carbazole biochemical assay. All animals are euthanized at 10 weeks post treatment by C02 inhalation.
Photodynamic Inactivation of Extracellular Growth Factors in Wound Healing
Three targeting moieties and one photosensitizer are used. Conjugates are prepared using
LDL (ligand for modified LDL receptor) , aleylated BSA
(ligand for scavenger receptor) , polystyrene nanospheres
(100-200 nm dia.) (ligand for macrophage phagocytosis) and the photosensitizer, ce6. Conjugates are characterized by SDS polyacrylamide gel electrophoresis, reverse phase HPLC, fluorescence and absorption spectrophotometry. Quantitative binding studies and cellular fluorescence imaging are carried out using a two photon fluorescence confocal microscopy system. Four cell lines are used for in vitro studies: a normal fibroblast cell line designated HSF, BALB/MK keratinocytes, a microvascular endothelial line designated Ea.hy.926, and a macrophage cell line designated J774.A1. The four cell lines are examined for in vitro uptake of LDL-ce6, Mal- BSA-ce6, and nanosphere-ce6 conjugates. Variables tested are concentration of conjugate, incubation time, and comparison of uptake at 37° and 4° C, to measure internalization.
Concentrations of conjugate and incubation time will be chosen for a light dose-cell survival response curve. Doses of PDT are administered to give survivals of 95%, 75%, 50%, and 25%. At various time points after PDT (1, 6, and 24 hours) , cells are harvested. Total RNA is extracted and assayed for the presence of mRNA coding for TGF3, VEGF, and IGF by Northern hybridization. Controls receiving conjugate alone or light alone are also tested for comparison. An immunofluorometric assay for VEGF in culture supernatant, which is capable of detecting 10 femtomoles of VEGF is used (Detmar et al., J. Invest . Dermatol . 105:44-50 (1995)). The culture supernatant from PDT-treated macrophages is tested to see
if it is capable of inducing the expression of VEGF by fibroblasts and keratinocytes, and if it has any itogenic effect on their growth rate. Similarly, the culture supernatant of treated fibroblasts and keratinocytes is tested to see if it has a mitogenic effect on microvascular endothelial cells.
Three wound models are used for in vivo testing. One model is a rabbit ear excisional model, which produces an avascular ulcer which can only heal from the edges. The second model is an FEL induced wound model on the rat dorsum. Intravenous and perilesional injection is compared for doses ranging from 50 μg to 1 mg/kg of ce6 equivalent. Various times are allowed for macrophage accumulation of conjugate (1, 6, and 24 hours) . In vivo fluorescence imaging is carried out by the two photon confocal fluorescence system. The lesions are irradiated with varying fluences of 666 nm light with appropriate controls. The rate of formation of granulation tissue, and re-epithelization is measured. Punch biopsies (2 mm) for total RNA extraction and analysis of TGF3, IGF, and VEGF mRNA by Northern hybridization are taken at early and late time points. At 3, 7, and 14 days post treatment, animals are sacrificed and the wounds removed. Strips of the wounds are removed and their strength is measured with a tensometer. Cross sections of the wounds are removed and analyzed histologically. They are stained by immunoperoxidase techniques to quantitate the number of macrophages, endothelial cells, and myofibroblasts. For studies on photodynamic therapy for abdominal adhesions, a third model, the rat model described by Langer et al. (J . Surg. Res . 59: 344-348 (1995)), is employed. In that model, rats develop intra- abdo inal adhesions that can be graded from grade 1 (thin easily separable) to grade 3 (extensive dense tissue
masses) (Elkins et al., Fertil . Steril . 41: 926-928 (1984) . Intra-abdominal photodynamic therapy is performed using methods described by Molpus et al. {Cancer Res . 56:1075-1082 (1996)) for treatment of experimental ovarian cancer. Photosensitizers or conjugates are injected intraperitoneally, followed by administration of red light. The red light is administered through an optical fiber that penetrates the abdominal wall and into a peritoneal cavity, which has been filled with intralipid as a light diffuser. To test whether intra-abdominal PDT can positively affect the degree of adhesion formation, four variables are investigated: (1) light dose, (2) conjugate dose, (3) time between cecal injury and the treatment, and (4) time between i.p injection of conjugate and the delivery of i.p. light. These parameters are varied systematically. Rats are sacrificed four weeks after treatment, and their adhesions are graded in a blind experimental design. Samples of the adhesion tissue are removed for histological staining.
Other embodiments are within the following claims.
Claims
1. A method for modulating the healing of a wound in a mammal, said method comprising the steps of:
(a) administering an effective amount of a photosensitizer to a mammal that has an unhealed or partially-healed wound;
(b) waiting for a time period wherein said photosensitizer reaches an effective tissue concentration at the wound site;
(c) photoactivating said photosensitizer at said wound site by delivering specifically to said wound site light of a effective wavelength and intensity, for an effective length of time, thereby modulating said healing of said wound in said mammal.
2. The method of claim 1, wherein said modulating includes hastening healing by administering a low dose of photodynamic therapy.
3. The method of claim 1, wherein said modulating includes inhibiting fibrosis by administering a high dose of photodynamic therapy.
4. The method of claim 1, wherein said photosensitizer is selected from the group consisting of: porphyrins, chlorins, bacteriochlorins, purpurins, phthalocyanines, naphthalocyanines, texaphyrins, and non- tetrapyrrole photosensitizers.
5. The method of claim 1, wherein said photosensitizer is targeted to macrophages or myofibroblasts by conjugation of a targeting moiety.
6. The method of claim 5, wherein said targeting moiety is selected from the group consisting of a protein, a peptide and a microparticle.
7. The method of claim 1, wherein the administration of said photosensitizer is systemic.
8. The method of claim 7, wherein said administration is at a dosage level between about 0.1 mg/kg and about 50 mg/kg.
9. The method of claim 8 , wherein said administration is at a dosage level between about 0.5 mg/kg and about 10 mg/kg.
10. The method of claim 1, wherein the administration said photosensitizer is local.
11. The method of claim 10, wherein said administration is parenteral.
12. The method of claim 10, wherein said administration is topical.
13. The method of claim 1, wherein said photoactivating step comprises delivering light by means of optical fibers.
14. The method of claim 1, wherein said photoactivating step comprises delivering light by means of transillumination.
15. The method of claim 1, wherein said photoactivating step comprises delivering light by means of open arthrotomy.
16. The method of claim 1, wherein said photoactivating step comprises delivering laser light.
17. The method of claim 1, wherein said modulating is performed prophylactically, prior to surgery, to reduce surgical adhesions.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2631596P | 1996-09-19 | 1996-09-19 | |
US60/026,315 | 1996-09-19 | ||
US08/741,816 US5913884A (en) | 1996-09-19 | 1996-10-31 | Inhibition of fibrosis by photodynamic therapy |
US08/741,816 | 1996-10-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998011827A1 true WO1998011827A1 (en) | 1998-03-26 |
Family
ID=26701081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/016188 WO1998011827A1 (en) | 1996-09-19 | 1997-09-12 | Modulation of wound healing by photodynamic therapy |
Country Status (2)
Country | Link |
---|---|
US (2) | US5913884A (en) |
WO (1) | WO1998011827A1 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000001414A1 (en) * | 1998-07-06 | 2000-01-13 | Pharmacyclics, Inc. | Use of texaphyrins in macrophage-mediated disease |
US6270749B1 (en) | 1996-12-11 | 2001-08-07 | Pharmacyclics, Inc. | Use of Texaphyrin in ocular diagnosis and therapy |
US6344050B1 (en) | 1998-12-21 | 2002-02-05 | Light Sciences Corporation | Use of pegylated photosensitizer conjugated with an antibody for treating abnormal tissue |
WO2010051636A1 (en) * | 2008-11-07 | 2010-05-14 | Klox Technologies Inc . | Combination of an oxidant and a photoactivator for the healing of wounds |
US8685466B2 (en) | 2009-07-17 | 2014-04-01 | Klox Technologies Inc. | Combination of an oxidant, a photosensitizer and a wound healing agent for oral disinfection and treatment of oral disease |
US8986719B2 (en) | 2005-11-09 | 2015-03-24 | Klox Technologies Inc. | Teeth whitening compositions and methods |
US9345648B2 (en) | 2006-11-09 | 2016-05-24 | Klox Technologies Inc. | Photoactivatable oxygen-evolving compositions and methods for teeth whitening |
US9655829B2 (en) | 2012-09-14 | 2017-05-23 | Valeant Pharmaceuticals International, Inc. | Compositions and methods for teeth whitening |
US10130706B2 (en) | 2013-03-14 | 2018-11-20 | Klox Technologies Inc. | Biophotonic materials and uses thereof |
US10207029B2 (en) | 2014-04-01 | 2019-02-19 | Klox Technologies Inc. | Tissue filler compositions and methods of use |
US10213373B2 (en) | 2012-04-20 | 2019-02-26 | Klox Technologies, Inc. | Chromophore combinations for biophotonic uses |
US10881736B2 (en) | 2013-07-03 | 2021-01-05 | Klox Technologies Inc. | Biophotonic compositions comprising a chromophore and a gelling agent for treating wounds |
WO2021030354A1 (en) * | 2019-08-12 | 2021-02-18 | Bioregentech, Inc. | Therapeutic systems, devices, and compositions with wound healing and tissue regenerative properties, uses thereof, and corresponding methods |
US11116841B2 (en) | 2012-04-20 | 2021-09-14 | Klox Technologies Inc. | Biophotonic compositions, kits and methods |
US11421349B2 (en) | 2014-10-31 | 2022-08-23 | Klox Technologies Inc. | Photoactivatable fibers and fabric media |
Families Citing this family (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9610967D0 (en) | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
IL119683A (en) * | 1996-11-25 | 2002-12-01 | Rachel Lubart | Method and device for light irradiation into tissue |
US8974363B2 (en) * | 1997-12-11 | 2015-03-10 | Provectus Pharmatech, Inc. | Topical medicaments and methods for photodynamic treatment of disease |
US6958148B1 (en) * | 1998-01-20 | 2005-10-25 | Pericor Science, Inc. | Linkage of agents to body tissue using microparticles and transglutaminase |
US20030176663A1 (en) * | 1998-05-11 | 2003-09-18 | Eidgenossische Technische Hochscule | Specific binding molecules for scintigraphy |
US8557298B2 (en) * | 1998-08-06 | 2013-10-15 | Provectus Pharmatech, Inc. | Medicaments for chemotherapeutic treatment of disease |
US20090117199A1 (en) * | 1998-08-06 | 2009-05-07 | Scott Timothy C | Method of treatment of cancer |
AU2412800A (en) * | 1999-01-15 | 2000-08-01 | Light Sciences Corporation | Noninvasive vascular therapy |
JP2002534483A (en) * | 1999-01-15 | 2002-10-15 | ライト サイエンシーズ コーポレイション | Therapeutic compositions for metabolic bone disorders or bone metastases |
US6602274B1 (en) * | 1999-01-15 | 2003-08-05 | Light Sciences Corporation | Targeted transcutaneous cancer therapy |
US20030114434A1 (en) * | 1999-08-31 | 2003-06-19 | James Chen | Extended duration light activated cancer therapy |
WO2001024825A2 (en) * | 1999-10-01 | 2001-04-12 | The General Hospital Corporation Doing Business As Massachusetts General Hospital | Significance of dosimetry in photodynamic therapy of injured arteries |
US7897140B2 (en) | 1999-12-23 | 2011-03-01 | Health Research, Inc. | Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents |
EP1267935A2 (en) * | 2000-01-12 | 2003-01-02 | Light Sciences Corporation | Novel treatment for eye disease |
US7073510B2 (en) * | 2000-02-11 | 2006-07-11 | The General Hospital Corporation | Photochemical tissue bonding |
JP5101778B2 (en) | 2000-02-11 | 2012-12-19 | ザ ジェネラル ホスピタル コーポレイション | Tissue adhesion by photochemical action |
US8215314B2 (en) * | 2000-02-11 | 2012-07-10 | The General Hospital Corporation | Photochemical tissue bonding |
WO2001062800A1 (en) * | 2000-02-24 | 2001-08-30 | Eidgenössische Technische Hochschule Zürich | Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis |
US6607522B1 (en) * | 2000-03-16 | 2003-08-19 | General Hospital Corporation | Methods for tissue welding using laser-activated protein solders |
GB2370992B (en) * | 2000-03-23 | 2002-11-20 | Photo Therapeutics Ltd | Therapeutic light source and method |
US6719778B1 (en) * | 2000-03-24 | 2004-04-13 | Endovascular Technologies, Inc. | Methods for treatment of aneurysms |
AU2001280754A1 (en) * | 2000-07-24 | 2002-02-05 | Research Development Foundation | Enhancement of photodynamic therapy by anti-angiogenic treatment |
US20030027151A1 (en) * | 2000-08-18 | 2003-02-06 | Warman Matthew L. | Regulator gene and system useful for the diagnosis and therapy of osteoporosis |
PL364358A1 (en) * | 2000-09-07 | 2004-12-13 | Schering Ag | Receptor in the edb fibronectin domain (ii) |
US6602275B1 (en) * | 2000-09-18 | 2003-08-05 | Jana Sullivan | Device and method for therapeutic treatment of living organisms |
US20020137901A1 (en) * | 2001-01-22 | 2002-09-26 | Cavanaugh Philip Gerard | Synthesis, and photodynamic therapy-mediated anti-cancer, and other uses of chlorin e6-transferrin |
GB0113899D0 (en) | 2001-06-07 | 2001-08-01 | Photocure Asa | Photodynamic therapy lamp |
GB0118251D0 (en) * | 2001-07-26 | 2001-09-19 | Photocure Asa | Method |
US20030125314A1 (en) * | 2001-12-03 | 2003-07-03 | Edie Zusman | Photodynamic therapy for the treatment of epilepsy |
EP1467760A2 (en) * | 2002-01-23 | 2004-10-20 | Light Sciences Corporation | Systems and methods for photodynamic therapy |
US6723750B2 (en) | 2002-03-15 | 2004-04-20 | Allergan, Inc. | Photodynamic therapy for pre-melanomas |
EP1517684B1 (en) | 2002-06-27 | 2009-07-22 | Health Research, Inc. | Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy |
US20050101582A1 (en) * | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
US20050250737A1 (en) * | 2003-11-12 | 2005-11-10 | Allergan, Inc. | Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods |
US20060141049A1 (en) * | 2003-11-12 | 2006-06-29 | Allergan, Inc. | Triamcinolone compositions for intravitreal administration to treat ocular conditions |
US20070224278A1 (en) | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
AU2005209201B2 (en) | 2004-01-20 | 2010-06-03 | Allergan, Inc. | Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
US8591885B2 (en) * | 2004-04-30 | 2013-11-26 | Allergan, Inc. | Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems |
US20050244471A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Estradiol derivative and estratopone containing sustained release intraocular implants and related methods |
US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
US8425929B2 (en) * | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
US8455656B2 (en) | 2004-04-30 | 2013-06-04 | Allergan, Inc. | Kinase inhibitors |
US8673341B2 (en) * | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
US20050244472A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intraocular drug delivery systems containing excipients with reduced toxicity and related methods |
US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
US20050244461A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Controlled release drug delivery systems and methods for treatment of an eye |
US20050244462A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Devices and methods for treating a mammalian eye |
US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
US20050244478A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Anti-excititoxic sustained release intraocular implants and related methods |
US20050244465A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Drug delivery systems and methods for treatment of an eye |
US8147865B2 (en) * | 2004-04-30 | 2012-04-03 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
US20070059336A1 (en) * | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
US7771742B2 (en) | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
US20050244458A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
US20050244500A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intravitreal implants in conjuction with photodynamic therapy to improve vision |
US20050244466A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Photodynamic therapy in conjunction with intraocular implants |
BRPI0510485A (en) | 2004-04-30 | 2007-11-13 | Allergan Inc | biodegradable intravitreal tyrosine kinase inhibitor implants |
US8119154B2 (en) * | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
JP2008505978A (en) * | 2004-07-12 | 2008-02-28 | アラーガン、インコーポレイテッド | Ophthalmic composition and eye disease treatment method |
CA2584970A1 (en) * | 2004-08-13 | 2006-02-16 | Derma Laser Inc. | Method for the treatment of mammalian skin tissues via pulse irradiation in the presence of a photoactive compound |
JP2008511420A (en) | 2004-08-30 | 2008-04-17 | スピネオベイションズ・インコポレーテッド | Methods of treatment of spinal disc injury |
GB0420888D0 (en) * | 2004-09-20 | 2004-10-20 | Photopharmica Ltd | Compounds and uses |
US20060188866A1 (en) * | 2005-02-18 | 2006-08-24 | Children's Hospital Oakland Research Institute | Diaminophenothiazine compositions and uses thereof |
US20090209508A1 (en) * | 2005-05-16 | 2009-08-20 | Universite De Geneve | Compounds for Photochemotherapy |
US20070036770A1 (en) * | 2005-08-12 | 2007-02-15 | Wagner Darrell O | Biologic device for regulation of gene expression and method therefor |
US7736382B2 (en) | 2005-09-09 | 2010-06-15 | Lockheed Martin Corporation | Apparatus for optical stimulation of nerves and other animal tissue |
US20080077200A1 (en) * | 2006-09-21 | 2008-03-27 | Aculight Corporation | Apparatus and method for stimulation of nerves and automated control of surgical instruments |
US8945197B1 (en) | 2005-10-24 | 2015-02-03 | Lockheed Martin Corporation | Sight-restoring visual prosthetic and method using infrared nerve-stimulation light |
US8744570B2 (en) * | 2009-01-23 | 2014-06-03 | Lockheed Martin Corporation | Optical stimulation of the brainstem and/or midbrain, including auditory areas |
US8956396B1 (en) | 2005-10-24 | 2015-02-17 | Lockheed Martin Corporation | Eye-tracking visual prosthetic and method |
US8709078B1 (en) | 2011-08-03 | 2014-04-29 | Lockheed Martin Corporation | Ocular implant with substantially constant retinal spacing for transmission of nerve-stimulation light |
US8792978B2 (en) | 2010-05-28 | 2014-07-29 | Lockheed Martin Corporation | Laser-based nerve stimulators for, E.G., hearing restoration in cochlear prostheses and method |
US8012189B1 (en) | 2007-01-11 | 2011-09-06 | Lockheed Martin Corporation | Method and vestibular implant using optical stimulation of nerves |
US8929973B1 (en) | 2005-10-24 | 2015-01-06 | Lockheed Martin Corporation | Apparatus and method for characterizing optical sources used with human and animal tissues |
US8475506B1 (en) | 2007-08-13 | 2013-07-02 | Lockheed Martin Corporation | VCSEL array stimulator apparatus and method for light stimulation of bodily tissues |
EP1779891A1 (en) | 2005-10-28 | 2007-05-02 | Abdula Kurkayev | Method of activating a photosensitizer |
US8999933B2 (en) * | 2006-01-18 | 2015-04-07 | Biolitec Pharma Marketing Ltd | Photodynamic cosmetic procedure and healing method |
US20070212385A1 (en) * | 2006-03-13 | 2007-09-13 | David Nathaniel E | Fluidic Tissue Augmentation Compositions and Methods |
US20090326435A1 (en) * | 2006-05-02 | 2009-12-31 | Green Medical, Inc. | Systems and methods for treating superficial venous malformations like varicose or spider veins |
WO2007130465A2 (en) * | 2006-05-02 | 2007-11-15 | Green Medical, Inc. | Systems and methods for treating superficial venous malformations like spider veins |
US7465312B2 (en) | 2006-05-02 | 2008-12-16 | Green Medical, Inc. | Systems and methods for treating superficial venous malformations like spider veins |
US20090028926A1 (en) * | 2007-07-25 | 2009-01-29 | Ceramoptec Industries Inc. | Method and mixture for in vivo photochemical cross-linking of collagen |
EP2068622A4 (en) * | 2006-07-28 | 2012-10-10 | Ceramoptec Gmbh | Method and mixture for in-vivo photochemical cross-linking of collagen |
US20080058905A1 (en) * | 2006-09-01 | 2008-03-06 | Wagner Darrell O | Method and apparatus utilizing light as therapy for fungal infection |
US20080076836A1 (en) * | 2006-09-01 | 2008-03-27 | Cardiac Pacemakers, Inc | Method and apparatus for using light to enhance cell growth and survival |
US20080058881A1 (en) * | 2006-09-01 | 2008-03-06 | Cardiac Pacemakers, Inc | Method and system for treating post-mi patients |
US8996131B1 (en) | 2006-09-28 | 2015-03-31 | Lockheed Martin Corporation | Apparatus and method for managing chronic pain with infrared light sources and heat |
US8498699B2 (en) * | 2008-10-03 | 2013-07-30 | Lockheed Martin Company | Method and nerve stimulator using simultaneous electrical and optical signals |
US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
US7883536B1 (en) | 2007-01-19 | 2011-02-08 | Lockheed Martin Corporation | Hybrid optical-electrical probes |
US7911053B2 (en) * | 2007-04-19 | 2011-03-22 | Marvell World Trade Ltd. | Semiconductor packaging with internal wiring bus |
US20080299172A1 (en) * | 2007-06-04 | 2008-12-04 | Stuart Young | Tissue repair implant |
IL184218A0 (en) * | 2007-06-26 | 2007-10-31 | Zidkiyahu Simenhaus | Photo-magnetic radiation device |
EP2644228A1 (en) | 2007-06-27 | 2013-10-02 | The General Hospital Corporation | Method and apparatus for optical inhibition of photodynamic therapy |
US20090082836A1 (en) * | 2007-09-20 | 2009-03-26 | Daniel Schell | Methods of applying phototherapy |
US20090105708A1 (en) * | 2007-10-23 | 2009-04-23 | Mcginnis William J | Dual frequency led/electrode surgical device, kit and method |
US20090105791A1 (en) * | 2007-10-23 | 2009-04-23 | Mcginnis William J | Light emitting medical garment device, kit and method of using |
WO2009067217A1 (en) * | 2007-11-20 | 2009-05-28 | Ceramoptec Industries, Inc. | Pdt assisted scar prevention and vision correction |
US9011508B2 (en) | 2007-11-30 | 2015-04-21 | Lockheed Martin Corporation | Broad wavelength profile to homogenize the absorption profile in optical stimulation of nerves |
US8253725B2 (en) * | 2007-12-28 | 2012-08-28 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Method and system for generating surface models of geometric structures |
US20100010549A1 (en) * | 2008-03-05 | 2010-01-14 | Neville Alleyne | device and method of minimally invasive extracapsular ligamentous augmentation for canine stifle ligament injuries |
US8469961B2 (en) * | 2008-03-05 | 2013-06-25 | Neville Alleyne | Methods and compositions for minimally invasive capsular augmentation of canine coxofemoral joints |
US20100004700A1 (en) * | 2008-03-05 | 2010-01-07 | Neville Alleyne | Method of treating tissue with a suspenson of tricalcium hydroxyapatite microspheres |
US20100016732A1 (en) * | 2008-07-17 | 2010-01-21 | Lockheed Martin Corporation | Apparatus and method for neural-signal capture to drive neuroprostheses or control bodily function |
WO2010040142A1 (en) | 2008-10-03 | 2010-04-08 | Lockheed Martin Corporation | Nerve stimulator and method using simultaneous electrical and optical signals |
US8492339B2 (en) * | 2009-10-26 | 2013-07-23 | Empire Technology Development Llc | Angiogenesis promoted by caged growth factors |
BR122017013201B1 (en) | 2009-11-09 | 2018-05-15 | Allergan, Inc. | COMPOSITION FOR STIMULATION OF HAIR GROWTH |
US8657859B2 (en) * | 2009-12-16 | 2014-02-25 | Advanced Veterinary Solutions | Implant for promoting stability of the canine stifle joint |
US8980174B2 (en) | 2011-05-13 | 2015-03-17 | Bactriblue, Ltd. | Methods and apparatus for reducing count of infectious agents in intravenous access system |
WO2012176023A1 (en) | 2011-06-23 | 2012-12-27 | Indian Institute Of Technology Kanpur | Hydrogel scaffolds for tissue engineering |
KR101385196B1 (en) | 2012-05-17 | 2014-04-14 | 주식회사 유니크메디케어 | Compositions for Improving or Facilitating Hair Growth Comprising a Photosensitizer-Peptide as an Active Ingredient Using Light Irradiation, and Methods thereof |
CN109602691A (en) | 2013-02-15 | 2019-04-12 | 阿勒根公司 | Sustained drug delivery implantation material |
US20160286801A1 (en) | 2013-03-15 | 2016-10-06 | Suncor Energy Inc. | Herbicidal Compositions |
US11000694B2 (en) | 2014-10-24 | 2021-05-11 | The Board Of Trustees Of The University Of Illinois | Use of lasers for treating and reversing fibrosis |
ES2693579T3 (en) | 2015-01-16 | 2018-12-12 | Spineovations, Inc. | Method of treatment of the intervertebral disc |
US10632324B2 (en) | 2017-04-27 | 2020-04-28 | 9127-4910 Quebec Inc. | Method for the treatment of skin tissues |
CA3092689A1 (en) | 2017-10-23 | 2019-05-02 | Patent Holding Company 001, Llc | Communication devices, methods, and systems |
RU181767U1 (en) * | 2018-04-16 | 2018-07-26 | Ринат Дамирович Сагдиев | DEVICE FOR PHOTODYNAMIC THERAPY OF PURULENT RAS |
US11934583B2 (en) | 2020-10-30 | 2024-03-19 | Datafeel Inc. | Wearable data communication apparatus, kits, methods, and systems |
CN113633771A (en) * | 2021-09-09 | 2021-11-12 | 中国医学科学院生物医学工程研究所 | Application of amino acid modified amino tetraphenyl porphyrin compound in preventing and treating fibrosis |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5409369A (en) * | 1991-10-15 | 1995-04-25 | Malcolite Corporation | Apparatus for making a wide angle light diffusing lens |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5368841A (en) * | 1993-02-11 | 1994-11-29 | The General Hospital Corporation | Photodynamic therapy for the destruction of the synovium in the treatment of rheumatoid arthritis and the inflammatory arthritides |
US5405369A (en) * | 1994-01-25 | 1995-04-11 | Medical College Of Ohio | Photochemical ablation of gastro-intestinal tissue for augmentation of an organ |
-
1996
- 1996-10-31 US US08/741,816 patent/US5913884A/en not_active Expired - Lifetime
-
1997
- 1997-09-12 WO PCT/US1997/016188 patent/WO1998011827A1/en active Application Filing
-
1998
- 1998-09-24 US US09/160,528 patent/US6107466A/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5409369A (en) * | 1991-10-15 | 1995-04-25 | Malcolite Corporation | Apparatus for making a wide angle light diffusing lens |
Cited By (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6270749B1 (en) | 1996-12-11 | 2001-08-07 | Pharmacyclics, Inc. | Use of Texaphyrin in ocular diagnosis and therapy |
WO2000001414A1 (en) * | 1998-07-06 | 2000-01-13 | Pharmacyclics, Inc. | Use of texaphyrins in macrophage-mediated disease |
US6344050B1 (en) | 1998-12-21 | 2002-02-05 | Light Sciences Corporation | Use of pegylated photosensitizer conjugated with an antibody for treating abnormal tissue |
US6554853B2 (en) | 1998-12-21 | 2003-04-29 | Light Sciences Corporation | Use of pegylated photosensitizer conjugated with an antibody for treating abnormal tissue |
US8986719B2 (en) | 2005-11-09 | 2015-03-24 | Klox Technologies Inc. | Teeth whitening compositions and methods |
US9345648B2 (en) | 2006-11-09 | 2016-05-24 | Klox Technologies Inc. | Photoactivatable oxygen-evolving compositions and methods for teeth whitening |
US10758744B2 (en) | 2008-11-07 | 2020-09-01 | Klox Technologies Inc. | Combination of an oxidant and a photoactivator for the wounds |
AU2009311234B2 (en) * | 2008-11-07 | 2013-05-02 | Klox Technologies Inc. | Combination of an oxidant and a photoactivator for the healing of wounds |
US8658219B2 (en) | 2008-11-07 | 2014-02-25 | Klox Technologies Inc. | Oxidatitive photoactivated skin rejeuvenation composition comprising hyaluronic acid, glucosamine, or allantoin |
US11020609B2 (en) | 2008-11-07 | 2021-06-01 | Klox Technologies Inc. | Methods and compositions for treatment of pigmented lesions |
US8911791B2 (en) | 2008-11-07 | 2014-12-16 | Klox Technologies Inc. | Method for acne treatment using an oxidative-photoactivated composition |
US8974833B2 (en) | 2008-11-07 | 2015-03-10 | Klox Technologies Inc. | Combination of an oxidant and a photoactivator for the healing of wounds |
US11691025B2 (en) | 2008-11-07 | 2023-07-04 | Klox Technologies Inc. | Methods and compositions for reversing or mitigating skin aging |
US8632822B2 (en) | 2008-11-07 | 2014-01-21 | Klox Technologies Inc. | Combination of an oxidant and a photoactivator for the healing of wounds |
US8986745B2 (en) | 2008-11-07 | 2015-03-24 | Klox Technologies Inc. | Oxidatitive photoactivated skin rejeuvenation composition comprising hyaluronic acid, glucosamine, or allantoin |
US8637086B2 (en) | 2008-11-07 | 2014-01-28 | Klox Technologies Inc. | Method for acne treatment using an oxidative-photoactivated composition |
US9375446B2 (en) | 2008-11-07 | 2016-06-28 | Klox Technologies Inc. | Oxidatitive photoactivated skin rejeuvenation composition comprising hyaluronic acid, glucosamine, or allantoin |
EA024827B1 (en) * | 2008-11-07 | 2016-10-31 | Клокс Текнолоджиз Инк. | Combination of an oxidant and a photoactivator for the healing of wounds |
US9597349B2 (en) | 2008-11-07 | 2017-03-21 | Klox Technologies Inc. | Combination of an oxidant and a photoactivator for the healing of wounds |
WO2010051636A1 (en) * | 2008-11-07 | 2010-05-14 | Klox Technologies Inc . | Combination of an oxidant and a photoactivator for the healing of wounds |
US10485986B2 (en) | 2008-11-07 | 2019-11-26 | Klox Technologies Inc. | Methods and compositions for treatment of pigmented lesions |
US10384072B2 (en) | 2008-11-07 | 2019-08-20 | Klox Technologies Inc. | Combination of an oxidant and a photoactivator for the healing of wounds |
US10149985B2 (en) | 2008-11-07 | 2018-12-11 | Klox Technologies Inc. | Methods and compositions for treating rosacea |
US10471147B2 (en) | 2009-07-17 | 2019-11-12 | Klox Technologies Inc. | Combination of an oxidant, a photosensitizer and a wound healing agent for oral disinfection and treatment of oral disease |
US8986746B2 (en) | 2009-07-17 | 2015-03-24 | Klox Technologies Inc. | Combination of an oxidant, a photosensitizer and a wound healing agent for oral disinfection and treatment of oral disease |
US10322179B2 (en) | 2009-07-17 | 2019-06-18 | Klox Technologies Inc. | Combination of an oxidant, a photosensitizer and a wound healing agent for oral disinfection and treatment of oral disease |
US11141482B2 (en) | 2009-07-17 | 2021-10-12 | Klox Technologies Inc. | Combination of an oxidant, a photosensitizer and a wound healing agent for oral disinfection and treatment of oral disease |
US8685466B2 (en) | 2009-07-17 | 2014-04-01 | Klox Technologies Inc. | Combination of an oxidant, a photosensitizer and a wound healing agent for oral disinfection and treatment of oral disease |
US9603929B2 (en) | 2009-07-17 | 2017-03-28 | Klox Technologies Inc. | Combination of an oxidant, a photosensitizer and a wound healing agent for oral disinfecton and treatment of oral disease |
US11331257B2 (en) | 2012-04-20 | 2022-05-17 | Klox Technologies Inc. | Biophotonic compositions and methods for providing biophotonic treatment |
US11723854B2 (en) | 2012-04-20 | 2023-08-15 | Fle International S.R.L. | Biophotonic compositions and methods for providing biophotonic treatment |
US10213373B2 (en) | 2012-04-20 | 2019-02-26 | Klox Technologies, Inc. | Chromophore combinations for biophotonic uses |
US11116841B2 (en) | 2012-04-20 | 2021-09-14 | Klox Technologies Inc. | Biophotonic compositions, kits and methods |
US10376455B2 (en) | 2012-04-20 | 2019-08-13 | Klox Technologies Inc. | Biophotonic compositions and methods for providing biophotonic treatment |
US9655829B2 (en) | 2012-09-14 | 2017-05-23 | Valeant Pharmaceuticals International, Inc. | Compositions and methods for teeth whitening |
US10130706B2 (en) | 2013-03-14 | 2018-11-20 | Klox Technologies Inc. | Biophotonic materials and uses thereof |
US11324823B2 (en) | 2013-03-14 | 2022-05-10 | Klox Technologies Inc. | Biophotonic materials and uses thereof |
US10881736B2 (en) | 2013-07-03 | 2021-01-05 | Klox Technologies Inc. | Biophotonic compositions comprising a chromophore and a gelling agent for treating wounds |
US10207029B2 (en) | 2014-04-01 | 2019-02-19 | Klox Technologies Inc. | Tissue filler compositions and methods of use |
US10772990B2 (en) | 2014-04-01 | 2020-09-15 | Klox Technologies Inc. | Tissue filler compositions and methods of use |
US11421349B2 (en) | 2014-10-31 | 2022-08-23 | Klox Technologies Inc. | Photoactivatable fibers and fabric media |
WO2021030354A1 (en) * | 2019-08-12 | 2021-02-18 | Bioregentech, Inc. | Therapeutic systems, devices, and compositions with wound healing and tissue regenerative properties, uses thereof, and corresponding methods |
Also Published As
Publication number | Publication date |
---|---|
US6107466A (en) | 2000-08-22 |
US5913884A (en) | 1999-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5913884A (en) | Inhibition of fibrosis by photodynamic therapy | |
EP0682517B1 (en) | Photodynamic treatment of synovium | |
Giraudeau et al. | Indocyanine green: photosensitizer or chromophore? Still a debate | |
CA2144327C (en) | Transcutaneous in vivo activation of photosensitive agents in blood | |
Cincotta et al. | Benzophenothiazine and benzoporphyrin derivative combination phototherapy effectively eradicates large murine sarcomas | |
AU2002340659B2 (en) | Photodynamic therapy for the treatment of hair loss | |
CA2273010C (en) | Use of green porphyrins for the manufacture of a medicament for the treatment of secondary cataracts | |
Keefe et al. | Photodynamic therapy of high‐grade cervical intraepithelial neoplasia with 5‐aminolevulinic acid | |
Molpus et al. | Intraperitoneal photoimmunotherapy of ovarian carcinoma xenografts in nude mice using charged photoimmunoconjugates | |
WO1991014456A2 (en) | Improved compositions for photodynamic therapy | |
JPH10508577A (en) | Photodynamic therapy in the treatment of selective cell inactivation and immune dysfunction disease in blood | |
Kim et al. | Photodynamic therapy of pigmented choroidal melanomas of greater than 3-mm thickness | |
US5952329A (en) | Benzophenothiazine and benzoporphyrin dye combination photodynamic therapy of tumors | |
Marcus et al. | Photodynamic therapy systems and applications | |
Richter et al. | Characterization of benzoporphyrin derivative, a new photosensitizer | |
DE69729004T2 (en) | PHOTODYNAMIC THERAPY FOR THE TREATMENT OF OSTEOSRTHRITIS | |
Abels et al. | Targeting of the tumor microcirculation by photodynamic therapy with a synthetic porphycene | |
Busetti et al. | High efficiency of benzoporphyrin derivative in the photodynamic therapy of pigmented malignant melanoma | |
Vonarx-Coinsman et al. | HepG2 human hepatocarcinoma cells: an experimental model for photosensitization by endogenous porphyrins | |
Davis et al. | Modified polyvinyl alcohol‐benzoporphyrin derivative conjugates as phototoxic agents | |
Martens et al. | In vitro and in vivo evaluation of hypericin for photodynamic therapy of equine sarcoids | |
Dellian et al. | Photodynamic eradication of amelanotic melanoma of the hamster with fast acting photosensitizers | |
Levy et al. | Photodynamic therapy of malignancies with benzoporphyrin derivative monoacid ring A | |
EP1633337A2 (en) | Methods of using nitroxides in conjunction with photosensitizers and sonosensitizers | |
Milanesi et al. | Experimental photodynamic therapy with tetrapropyl-porphycene: ultrastructural studies on the mechanism of tumour photodamage |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998514765 Format of ref document f/p: F |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |